Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus bevacizumab as first-line therapy in advanced NSCLC
ChiCTR-OPN-16010148Phase 4Not yet recruiting
- Sponsor
- Taizhou People's Hospital
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gefitinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Taizhou People's Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
gefitinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPN-16010148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16010148.